Egypt
Tuberculosis profile
Population  2012 81 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.38 (0.35–0.4) 0.46 (0.43–0.5)
Mortality (HIV+TB only) 0.045 (0.04–0.054) 0.06 (0.05–0.07)
Prevalence  (includes HIV+TB) 23 (12–39) 29 (15–48)
Incidence  (includes HIV+TB) 14 (12–16) 17 (14–19)
Incidence (HIV+TB only) 0.13 (0.11–0.16) 0.17 (0.14–0.19)
Case detection, all forms (%) 62 (54–73)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 4 295 (53) Relapse 306 (50)
Smear-negative 903 (11) Treatment after failure 104 (17)
Smear-unknown / not done 34 (<1) Treatment after default 106 (17)
Extrapulmonary 2 915 (36) Other 90 (15)
Other 0 (0)      
Total new 8 147   Total retreatment 606  
           
Other (history unknown) 0        
Total new and relapse 8 453   Total cases notified 8 753  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.9 1.1 1.0
Age < 15 31 127 392
Laboratories 2012
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) <0.1
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 88  
Retreatment 72  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 514 (17)
HIV-positive TB patients 17 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 17 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 17 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.4 (1.9–4.9) 25 (21–29)
MDR-TB cases among notified pulmonary
TB cases
180 (99–260) 150 (130–180)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 31 (<1%) 438 (72%) 469
Laboratory-confirmed MDR-TB cases 8 108 116
Patients started on MDR-TB treatment     52
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data